Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle...
Transcript of Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle...
![Page 1: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/1.jpg)
Sickle Cell Disease:Where are we?
Kunle Adekile, MD, PhDProfessor and ChairmanDepartment of Pediatrics
Kuwait University
ChairmanNigeria SCD Network
![Page 2: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/2.jpg)
Outline• Hunter‐Gatherer to Settler
– Pre‐Malaria Era• Malaria Selective Pressure• Genetic Epidemiology• Pathophysiology of SCD• Morbidity and mortality patterns• Contributions from Nigeria• Nigerian SCD Network• Priorities
![Page 3: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/3.jpg)
Origins of Man ‐ Hunter/Gatherer (~10,000 BC)
![Page 4: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/4.jpg)
Agricultural Revolution ‐ Neolithic(3,000 – 500 BC)
Infections became endemic & transmission rate increased
![Page 5: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/5.jpg)
Malaria• Protozoal disease transmitted by the anopheles mosquito
• Prehistoric man suffered from the disease• Probably originated in Africa and accompanied human migration to the Mediterranean, India and South East Asia
• Today about 500 million people are exposed and 2‐3 million die annually
![Page 6: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/6.jpg)
Malaria Transmission Rate
• Population density of hunter/gatherer so low that that malarial parasites could not maintain the high endemicities and transmission rates that occur among high‐density tropical agriculturalists
• It is also among the latter that the highest frequencies of Hb variants are found (Livingstone 1989)– Balanced polymorphism from advantage conferred by heterozygotes against malaria complications
![Page 7: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/7.jpg)
King Tut, 14th Century Pharaoh
• Had osteonecrosis• Walked with a cane• Died at age of 19 years• Believed to have SCD
![Page 8: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/8.jpg)
Distribution of Malaria and HbS
![Page 9: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/9.jpg)
Selective Effect of Malaria on the S Trait
![Page 10: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/10.jpg)
BMJ 22 MAY 1971;2(5759):445‐6
Severe Malarial Infection in a Patient with Sickle-cell AnaemiaAdelola Adeloye, L. Luzzatto, G. M. Edington
Lancet 295 (7642): 319-322, 1970
INCREASED SICKLING OF PARASITISED ERYTHROCYTES AS MECHANISM OF RESISTANCE AGAINST MALARIA IN THE SICKLE-CELL TRAIT
Lucio Luzzatto, E.S. Nwachuku-Jarrett, S. Reddy
Ann Trop Med Parasitol. 1979 Apr;73(2):161-72.
Abnormal haemoglobins in the Sudan savanna of Nigeria. I. Prevalence of haemoglobinsand relationships between sickle cell trait, malaria and survival.
Fleming AF, Storey J, Molineaux L, Iroko EA, Attai ED.
![Page 11: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/11.jpg)
![Page 12: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/12.jpg)
Nagel & Ranney, 1990
Multicentric Origin on S Mutation
![Page 13: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/13.jpg)
SD Grosse et al, Am J Prev Med 2011
![Page 14: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/14.jpg)
Pathophysiology of Sickle Cell Disease(Steinberg 1999)
![Page 15: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/15.jpg)
Rees at al, Lancet 2010
![Page 16: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/16.jpg)
Secondary organ damage
Silent infarction
Priapism Cholelithiasis
Functional asplenia
Retinopathy
Renal failure
Ulcers Microalbuminuria
Osteonecrosis
Iron overload
Elevated tricuspidregurgifation
Cardiomyopathy
![Page 17: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/17.jpg)
Cause of deathchildren versus adults
Powars et al Medicine 2005
![Page 18: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/18.jpg)
SD Grosse et al, Am J Prev Med 2011
Mortality in African SCD Patients
![Page 19: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/19.jpg)
![Page 20: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/20.jpg)
![Page 21: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/21.jpg)
KL Haskell, Am J Prev Med 2010
![Page 22: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/22.jpg)
SCD is a Public Health Issue
• Enabling Act of parliament– National Policy
• Game Changers – Counseling & health education– Newborn screening– Penicillin prophylaxis– Hydroxyurea– Transcranial Doppler
• Chronic transfusion to prevent stroke
![Page 23: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/23.jpg)
![Page 24: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/24.jpg)
Stroke risk increases witqqqPredictive Value of TCD in SCD Stroke
TCD flow rate
Reproduced from Adams RJ, et al. Control Clin Trials. 1998;19:110-29. © 1998 Massachusetts Medical Society. All rights reserved.
0.4
0.5
0.6
0.7
0.8
0.9
1
0 5 10 15 20 25 30 35
Time (months)
Prob
abili
ty o
f rem
aini
ng s
trok
e-fr
ee
< 170 cm/s Normal170–199 cm/s Conditional 200 cm/s Abnormal
p = 0.0001
![Page 25: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/25.jpg)
Hydroxyurea suggested modes of action
• HbF induction• Cell count reduction• Reduces cell adhesion• Reduces haemolysis• Induces NO release
Ware R. Blood. 2010
![Page 26: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/26.jpg)
Hydroxyureaoverall survival
Voskaridou et al. Blood 2010
0
100
80
60
40
20
0
Surv
ival
pro
babi
lity
(%)
5 10 15 20
Survival (years)
Patients not receiving hydroxyurea (n = 199)10-year survival: 68%
Patients receiving hydroxyurea (n = 131)10-year survival: 86%
p = 0.001
![Page 27: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/27.jpg)
Hydroxyurearesponse per genotype
Reduction in mortality was observed across HbSS and HbSβ0
groups, but not in HbSβ+ patients
0
100
80
60
40
20
0
Surv
ival
pro
babi
lity
(%)
5 10 15 20Survival (years)
Patients not receiving hydroxyurea (N = 58)
Patients receiving hydroxyurea (N = 57)
p = 0.001
HbSβ0
100
80
60
40
20
0Surv
ival
pro
babi
lity
(%)
0 5 10 15 20Survival (years)
Patients not receiving hydroxyurea (N = 9)
Patients receiving hydroxyurea (N = 24)
p < 0.001
HbSS
60
100
80
40
20
00
Surv
ival
pro
babi
lity
(%)
5 10 15 20Survival (years)
Patients not receiving hydroxyurea (N = 56)
Patients receiving hydroxyurea (N = 37)
p = 0.369
HbSβ+
![Page 28: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/28.jpg)
Transfusion in SCDincreasing use…
• 41% of all patients received ≥ blood transfusions in 10 years• Increasing % of transfused patients (from 17.8% to 23.9%)• Increase due to exchange transfusions and acute pain treatment• More “indications”: renal failure, ulcers, lung disease, priapism
Drasar et al. Br J Haematol. 2011.
Blo
od u
sage
/pat
ient
yea
r
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
3.5
0
2.5
4.5
1.5
3.0
2.0
4.0
1.0
0.5
Total blood usageBlood usage: acuteBlood usage: planned Blood usage: exchangeBlood usage: top-up
Acute chestsyndrome/
bronchopneumonia
Cholecystitis/sicklehepatopathy/abdominalcrisis/acute renal failure
Acute stroke Acute painfulepisode
35%
0%
25%
45%
15%
30%
20%
40%
10%
5%
2000–20012008–2009
![Page 29: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/29.jpg)
Transfusion in SCDincreasing use…
• 41% of all patients received ≥ blood transfusions in 10 years• Increasing % of transfused patients (from 17.8% to 23.9%)• Increase due to exchange transfusions and acute pain treatment• More “indications”: renal failure, ulcers, lung disease, priapism
Drasar et al. Br J Haematol. 2011.
Blo
od u
sage
/pat
ient
yea
r
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
3.5
0
2.5
4.5
1.5
3.0
2.0
4.0
1.0
0.5
Total blood usageBlood usage: acuteBlood usage: planned Blood usage: exchangeBlood usage: top-up
Acute chestsyndrome/
bronchopneumonia
Cholecystitis/sicklehepatopathy/abdominalcrisis/acute renal failure
Acute stroke Acute painfulepisode
35%
0%
25%
45%
15%
30%
20%
40%
10%
5%
2000–20012008–2009
![Page 30: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/30.jpg)
Recent publications from Nigeria
![Page 31: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/31.jpg)
Prevalence of Sensorineural Hearing Loss In Nigerian SCD Patients
• Odetoyinbo and Adekile. Ann Otol Rhinol Laryngol. 1987; 96:258 – Studied children 6 – 15 years old found prevalence of 21.5%
• Mgbora and Emodib. Int J Ped Otorhinol 2004;68:1413– Studied children 6 – 19 years; found prevalence of 13.4%
• Aderibigbe, Ologe and Oyejola J Natl Med Assoc 2005; 97:1135– Studied adult patients 16 – 48 years; reported prevalence of 4.3%
• Alabi et al. Int J Ped Otorhinol 2008;72:659– Studied children 4 – 15 years, found a prevalence of 3.8%
![Page 32: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/32.jpg)
Stroke and Neurological Problems
• Fatunde et al. Afr J Med Med Sci. 2005– In a 15‐year review of children with stroke in a teaching hospital,
among 31 case, 27 (87%) had SCD, all Hb SS with 1 HbSC– This was a frequency of 5.4% of patients being followed in the hospital– The mean age at first stroke was 6.8 years– Of the 7 patients that had CT, 5 had infarction and 2 hemorrhage
• Kehinde et al J Natl Med Ass 2008– Questionnaire study of ~600 SCD patients and equal number of
controls• 76 % of SCD and 32% of controls had neurological manifestations
– Among children: stroke, febrile seizures and headaches– Among adolescents and adults: paraplegia, epileptic seizures and sensory neuropathies
![Page 33: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/33.jpg)
Proteinuria among Adult Nigerian SCD Patients
• Abdu et al. Ann Afr Med 2011• studied 200 adult patients
– Serum electrolytes/urea and eGFR in addition to 24 hour urine for proteinuria
– 28% had significant proteinuria• Among the males with proteinuria, 50% had chronic renal disease
![Page 34: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/34.jpg)
Avascular Necrosis
• Akinyoola et al Nig Postgrad Med J 2007– Retrospective study of 416 patients in Ile‐Ife– 340 SS and 76 SC– 66(15.9%) had clinical and radiological evidence of AVNFH
• 80% were SS• 60.3% presented with stage IV disease
![Page 35: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/35.jpg)
Gallstones in Nigerian SCD Patients
• Bojuwoye et al Trop Doc 2006– 100 patients aged 15 – 50 years– Overall prevalence of 28%– 15 ‐19 years 8%– 20 – 24 years14%– 25 – 29 years 3%– 30 – 34 years 2%– 35 – >39 years 1%
• +ve association with BMI, SS crises, reticulocyte, serum total bilirubin, AST and ALT
• Durosinmi et al Afr J Med Sci– Among adults (18 – 50yrs), found prevalence of 24.2%
• Nzeh and Adedoyin Ped Radiol 1989– Among chioldren (2-16 years), found aprevalence of 4.8%
![Page 36: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/36.jpg)
Nigerian SCD Network
• Established in 2010• Brings together Nigerian SCD experts both in the country and in the Diaspora including physicians, scientists, social workers, NGOs and patients (currently ~120 members)
• Currently have
90
35Nigeria
Diaspora
![Page 37: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/37.jpg)
Objectives
• Document activities of SCD‐related groups in the country
• Uniform management and counseling guidelines• Pursue the establishment of a national SCD policy• Liaise with internal and external funding agencies to promote training, research and care
• Establish partnerships and collaborations with external centers of excellence (within and outside Africa)
• Organize workshops and conferences within the country
![Page 38: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/38.jpg)
Working Groups
• Education, Guidelines and Protocols• National SCD Policy• Research (Infections, Hydroxyurea, Natural History, Phenotypic characteristics/diversity)
• Newborn Screening• Finance and Publicity
![Page 39: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/39.jpg)
Achievements• National policy on non‐communicable diseases (NCD) ‐ 2010
– Incorporating SCD policy• Position paper presented by the Nigerian President at the 2011 UN
Summit on NCDs• Informational, educational and counseling (IEC) materials and
management guidelines for SCD have been produced• Advocacy for the provision of pneumococcal vaccines for children under
the EPI• Adaptation of the NIH parents’ handbook for Nigeria• Registry of dedicated SCD clinics in the country • Pilot newborn screening schemes have been established in several states
of the country• Six model comprehensive SCD centers are being established in the country
by the Federal Government (Lagos, Abakiliki, Keffi, Kebbi, Gombe, Bayelsa)• A comprehensive Bill for an Act for the Prevention, Control and
Management of SCD is now before the National Assembly.
![Page 40: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/40.jpg)
Collaborations• Several partnerships are already active in different parts of the country involved with research and other projects including the following: – Sickle cell cohort study– Infection surveillance (Michigan State University)– Pilot newborn screening programs (King’s and Guy’s Hospitals, London, University of Chicago, Connecticut State Public Health Department and US Association of Public Health Laboratories,)
– Genomic studies (H3Africa, African Pharmacogenomics network, Sickle CHARTA)
– Educational grants (FIOCRUZ Foundation, Bahia, Brazil)• Close contact with the Global SCD Network
![Page 41: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/41.jpg)
Training
![Page 42: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/42.jpg)
Counselling
![Page 43: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/43.jpg)
Blood sampling
![Page 44: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/44.jpg)
Dedicated SCD Clinics/Centers in Nigeria
![Page 45: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/45.jpg)
No. Clinic* City Adult/Peds ~No. of patients
Medical Records (Y/N)
Database (Y/N)
Folic Acid(Y/N)
Penicillin(Y/N)
Malaria Prophylaxis (Y/N)
Hydroxyurea (Y/N)
Ciklavit
1 ABUTH Zaria Adult/Ped 1,150 Y N Y N Y Y N2 ABUTH Zaria Ped 1,700 Y Y Y Y Y N N3 AKTH Kano Adult 270 Y Y Y Y Y N N4 AKTH Kano Ped 1,300 Y Y Y Y Y Y N5 FMCA Asaba Ped 100 Y N Y Y Y N Y6 LASUTH Lagos Adult 2,200 Y Y Y N Y N Y7 LASUTH Lagos Ped 670 Y Y Y N Y N N8 LUTH Lagos Adult 1,000 Y Y Y Y Y Y Y9 LUTH Lagos Ped 1,500 Y Y Y Y Y Y Y10 MMSH Kano Adult/Ped 11,000 Y Y Y Y Y Y N11 OAUTHC Ile‐Ife Adult 200 Y Y Y N Y N Y12 OAUTHC Ilesha Ped 45 Y Y Y N Y N Y
13 SCF Isolo Mixed 270 Y Y Y N N N Y14 UCH Ibadan Ped 500 Y Y Y N Y Y N15 UCH Ibadan Adult 1,000 Y N Y N Y N N16 UNTH Enugu Ped 350 Y Y Y N Y N N
Table 1. Characteristics of Clinics and Common Practices
![Page 46: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/46.jpg)
No Clinic City Electronic cell counter
Hb Electro‐phoresis
HPLC Newbornscreening
IEF Micro‐biology Lab
Chemistry lab
Molecular biology lab
CT MRI TCD**
1 ABUTH Zaria Y Y N N N Y Y N Y Y Y2 ABUTH Zaria Y Y N N N Y Y N Y Y Y3 AKTH Kano Y Y N N N Y Y N Y Y N4 AKTH Kano Y Y N N N Y Y N Y Y N5 FMCA Asaba N Y N N N Y Y N N N N6 LASUTH Lagos Y Y N N N Y Y N Y Y Y7 LASUTH Lagos Y Y N N N Y Y N Y Y N8 LUTH Lagos Y Y N N N Y Y Y Y Y Y9 LUTH Lagos Y Y N N N Y Y Y Y Y Y10 MMSH Kano N Y N N N Y Y N N N N11 OAUTHC Ile‐Ife Y Y Y N N Y Y N Y Y N12 OAUTHC Ilesha N Y N N Y Y Y N Y N N13 SCF Lagos Y Y Y N N Y Y Y N N N14 UCH Ibadan Y Y N N N Y Y N Y Y Y15 UCH Ibadan Y Y N N N Y Y N Y Y Y16 UNTH Ituku Y Y N N N Y Y Y Y N N
Table 2. Facilities Available in the Different Clinics/Hospitals
![Page 47: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/47.jpg)
Immediate Priorities• Capacity building
– Training and updating physicians• Workshops and conferences• MSc (UCL), Masters & Doctorates (Brazil)
– Laboratory technicians– Counselors
• Data collection– Streamlined and uniform data collection in all center– Central point
• Liaison with FMOH, State governments and other stakeholders– Policy– Guidelines and management protocols– Act of parliament
![Page 48: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/48.jpg)
ANPA Potential Contributions• Act as SCD advocates
– Government, parliament, NGOs etc• Sponsorships
– Training at different levels– Workshops– Conferences
• Expert consultations and teaching• Donation of equipment
– HPLC– TCD– Computers
![Page 49: Sickle Cell Disease: Where are we? - ANPA Cell Disease: Where are we? ... Pathophysiology of Sickle Cell Disease ... • Pilot newborn screening schemes have been established in several](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ae141d37f8b9a1c248e2fd1/html5/thumbnails/49.jpg)
Thank you